Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor
08. Oktober 2021 06:00 ET
|
Relay Therapeutics, Inc.
Interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor that has not shown to be limited by off-target toxicities of hyperphosphatemia (FGFR1) and diarrhea (FGFR4) RLY-4008...
Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα
07. Oktober 2021 08:50 ET
|
Relay Therapeutics, Inc.
RLY-2608 preferentially binds mutant PI3Kα at a novel allosteric site discovered by the Dynamo™ platform Preclinically, achieved tumor regressions in vivo with significantly reduced impact on glucose...
Relay Therapeutics to Present Clinical Data on RLY-4008 and Preclinical Data on RLY-2608 at AACR-NCI-EORTC Molecular Targets Conference
13. September 2021 06:00 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading...
Relay Therapeutics Announces Corporate Updates and Reports Second Quarter 2021 Financial Results
12. August 2021 16:05 ET
|
Relay Therapeutics, Inc.
Company selected RLY-2608 as PI3Kα mutant inhibitor development candidate and plans to initiate first-in-human study in the first half of 2022 RLY-2608 potently inhibits mutants H1047X, E542X, and...
Relay Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Highlights
05. August 2021 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
02. Juni 2021 06:00 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in fireside chats at the Goldman Sachs 42nd Annual Global Healthcare...
Relay Therapeutics to Participate in Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit
14. Mai 2021 06:00 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit...
Relay Therapeutics Reports First Quarter 2021 Financial Results
13. Mai 2021 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading...
Relay Therapeutics Strengthens Computational Leadership Team with Addition of Patrick Riley, Ph.D.
10. Mai 2021 06:00 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading...
Relay Therapeutics to Participate in Fireside Chat at Bank of America 2021 Health Care Conference
05. Mai 2021 06:00 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of America 2021 Health Care Conference on...